Carcinoma papilar de tiroides metastásico refractario a Iodo 131 con expectancia de vida prolongada con Lenvatinib: Reporte de caso
DOI:
https://doi.org/10.35319/rmsp.2026119Resumen
El carcinoma papilar de tiroides (CPT), corresponde a la neoplasia maligna de tiroides más frecuente, puede presentarse a cualquier edad, aunque suele rondar entre los 25 a 50 años, tiene un pronóstico excelente con una supervivencia a los 10 años superior al 95%, es característica la lobectomía en lesiones pequeñas que por su tamaño no requerirán terapia con yodo radiactivo-131.
Citas
Kumar V, Abbas A, Aster J, editors. Robbins & Cotran Pathologic Basis of Disease. 10th ed. Vol 2. Philadelphia: Elsevier; 2020.
Takeuchi S, Shiga T, Hirata K, Taguchi J, Magota K, Ariga S, et al. Early prediction of lenvatinib treatment efficacy by using18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non randomized single-arm multicenter observational study. BMJ Open [Internet]. 1 de agosto de 2018;8(8):e021001. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC6119439/
Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer. The Journal Of Clinical Endocrinology & Metabolism [Internet]. 2 de febrero de 2015;100(4):1529-36. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC4399282/
Hadad B, Askari E, Zakavi SR, Aryana K, Erfani S, Sahafi P, et al. Case Report: Regaining radioiodine uptake following PRRT in radioiodine-refractory thyroid cancer: A new re differentiation strategy? Frontiers In Nuclear Medicine [Internet]. 17 de enero de 2023;2:1071022. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC11440960/
Wirth LJ, Durante C, Topliss DJ, Winquist E, Robenshtok E, Iwasaki H, et al. Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit. The Oncologist [Internet]. 25 de marzo de 2022;27(7):565-72. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC9256022/
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. New England Journal Of Medicine [Internet]. 11 de febrero de 2015;372(7):621-30. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25671254/
Roof L, Geiger JL. Clinical utility of cabozantinib in the treatment of locally advanced or metastatic differentiated thyroid carcinoma: Patient selection and reported outcomes. Cancer Manag Res [Internet]. 2023 [citado el 18 de enero de 2026];15:343–50. Disponible en: https://www.dovepress.com/clinical-utility-of-cabozantinib-in-the-treatment-of-locallyadvanced--peer-reviewed-fulltext-article-CMAR
Kandeel A, Abdou A, Eltahlawy E, Anwar H. Causes and Clinical Impact of Loss to Follow Up in Patients with Differentiated Thyroid Cancer in Nuclear Medicine Department, single institution experience. [Internet]. Journal Of Nuclear Medicine. 2023. Disponible en: https://jnm.snmjournals.org/content/64/supplement_1/P1028
RECIST 1.1 – RECIST. (s. f.). https://recist.eortc.org/recist-1-1-2/
Liu H, Yang D, Li L, Tu Y, Chen C, Sun S. Appraisal of radioiodine refractory thyroid cancer: advances and challenges [Internet]. 2020. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC7407348/
Boucai L. An update on redifferentiation therapy for radioiodine refractory thyroid cancer. Endocrinol Metab Clin North Am [Internet]. 2025;54(3):419–31. Disponible en: http://dx.doi.org/10.1016/j.ecl.2025.03.012
Gianoukakis AG, Dutcus CE, Batty N, Guo M, Baig M. Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocrine Related Cancer [Internet]. 11 de mayo de 2018;25(6):699-704. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC5958278/
Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ [Internet]. 4 de noviembre de 2020;371:m4087. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC7610021/
Capdevila J, Galofré JC, Grande E, Llopis CZ, Asensio TR y C, González EN, et al. Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI). Clinical & Translational Oncology [Internet]. 4 de octubre de 2016;19(3):279-87. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27704399/
Zhu C, Ma X, Hu Y, Guo L, Chen B, Shen K, et al. Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis. Oncotarget [Internet]. 14 de junio de 2016;7(28):44545-57. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC5190117/
Suzuki S, Horinouchi A, Uozumi S, Matsuyama C, Kamata H, Kaneko A, et al. Impact of outpatient pharmacy interventions on management of thyroid patients receiving lenvatinib. SAGE Open Medicine [Internet]. 1 de enero de 2020;8:2050312120930906. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32587691/
Ohno K, Shibata T, Ito K. Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells. Cancer Science [Internet]. 20 de junio de 2022;113(9):3193- 210. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC9459297/#cas15465-sec-0018
Cirello V, Colombo C, Tosi D, Manzo A, Borghi MO, Gianelli U, et al. TP53 Alterations Are Associated With Poor Response to Lenvatinib in Patients With Advanced Thyroid Cancer. The Journal Of Clinical Endocrinology & Metabolism [Internet]. 1 de febrero de 2025;110(10):e3353-65. Disponible en: https://pubmed.ncbi.nlm.nih.gov/39891677/
Brose MS, Robinson BG, Sherman SI, Jarzab B, Lin C-C, Vaisman F, et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer [Internet]. 2022;128(24):4203–12. Disponible en: http://dx.doi.org/10.1002/cncr.34493
Gubbi S, Koch CA, Klubo-Gwiezdzinska J. Peptide receptor radionuclide therapy in thyroid cancer. Front Endocrinol (Lausanne) [Internet]. 2022;13:896287. Disponible en: http://dx.doi.org/10.3389/fendo.2022.896287
Garbar V, Richter S. Palliative radiation therapy for bone metastases [Internet]. StatPearls - NCBI Bookshelf. 2024. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK603757/
Chen H, Roberts JR, Ball DW, Eisele DW, Baylin SB, Udelsman R, et al. Effective Long-term Palliation of Symptomatic, Incurable Metastatic Medullary Thyroid Cancer by Operative Resection. Annals Of Surgery [Internet]. 1 de junio de 1998;227(6):887-95. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC1191398/
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2026 Revista Médica San Pablo
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
